<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------
FORM 10-Q
QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarter ended Commission File
March 31, 1997 No. 1-9767
----------------------
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
Delaware 94-2579751
(State or other (I.R.S. Employer
jurisdiction of Identification
incorporation or No.)
organization)
9162 Eton Avenue, Chatsworth CA. 91311
(Address of principal executive offices) (Zip Code)
Telephone Number: 818-709-1244
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
Yes X No _________
The number of shares of Common Stock of the registrant outstanding
as of May 8, 1997 was 5,991,388.
<PAGE> 2
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
INDEX TO FORM 10-Q
Three months ended March 31, 1997 and 1996
<TABLE>
<CAPTION>
PAGE
<S> <C> <C>
PART 1 - FINANCIAL INFORMATION
ITEM 1 - Consolidated Financial Statements
Consolidated Balance Sheets............................................2
Consolidated Statements of Operations..................................3
Consolidated Statements of Cash Flows..................................4
Notes to Consolidated Financial Statements.............................5
ITEM 2 - Management's Discussion and Analysis of
Financial Condition and Results of Operations..................8
PART 2 - OTHER INFORMATION
ITEM 1 - Legal Proceedings............................................13
ITEM 6 - Exhibits And Reports on Form 8-K
(a) Exhibits.........................................................13
(b) Reports on Form 8-K..............................................13
SIGNATURE........................................................................13
</TABLE>
1
<PAGE> 3
PART 1 FINANCIAL INFORMATION
ITEM 1 - CONSOLIDATED FINANCIAL STATEMENTS
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
ASSETS
At December 31, At March 31,
1996 1997
------------ ------------
(unaudited)
<S> <C> <C>
Current assets:
Cash and cash equivalents $ 3,602,535 $ 2,018,028
Short-term investments 667,589 400,000
Accounts receivable, net of allowance for doubtful
accounts of $278,766 in 1996 and $285,819 in 1997 5,207,933 4,581,301
Inventories 4,838,206 4,430,353
Prepaid expenses and other current assets 163,465 146,752
Deferred tax asset 936,500 1,057,500
------------ ------------
Total current assets 15,416,228 12,633,934
Property and equipment, at cost, net of accumulated depreciation 1,947,713 1,718,458
Purchased intangibles 10,324,760 10,069,617
Software development costs, net of accumulated amortization of
$847,880 in 1996 and $931,623 in 1997 920,972 961,930
Deferred warrant costs 1,155,452 1,122,808
Deferred tax asset 7,276,250 7,276,250
Other assets 818,870 1,094,150
------------ ------------
Total assets $ 37,860,245 $ 34,877,147
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Short-term borrowings $ 1,334,755 1,334,755
Current portion of long term debt 2,600,000 1,600,000
Accounts payable 4,587,407 3,474,792
Accrued expenses 3,901,071 3,231,739
Deferred income - service contracts 799,523 850,879
Deferred income - other 279,591 227,096
------------ ------------
Total current liabilities 13,502,347 10,719,261
Subordinated note payable 7,000,000 7,000,000
Deferred income - service contracts and other 193,219 215,103
Notes payable, long-term portion 3,400,000 3,100,000
------------ ------------
Total liabilities 24,095,566 21,034,364
Commitments and contingencies
Shareholders' equity:
Preferred stock, $.01 par value
Authorized: 3,000,000 shares
Convertible Series A,
Shares issued and outstanding: 3,000 in 1996 and 1997
($3,000,000 liquidation preference) 30 30
Common stock, $.01 par value
Authorized: 15,600,000 shares
Shares issued and outstanding:
1996 - 5,911,890, 1997 - 5,991,388 59,118 59,913
Additional paid-in capital 36,311,535 36,681,575
Treasury stock, at cost (26,240 shares in 1996 and 1997) (103,500) (103,500)
Unearned compensation (385,879) (439,933)
Foreign currency translation adjustment 37,791 1,189
Accumulated deficit (22,154,416) (22,356,491)
------------ ------------
Total shareholders' equity 13,764,679 13,842,783
------------ ------------
Total liabilities and shareholders' equity $ 37,860,245 $ 34,877,147
============ ============
</TABLE>
- ---------------
The accompanying notes are an integral part of these consolidated financial
statements.
2
<PAGE> 4
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
<TABLE>
<CAPTION>
For the three months ended March 31,
1996 1997
----------- -----------
<S> <C> <C>
Sales of IVD imaging systems $ 869,139 $ 2,479,290
Sales of IVD imaging supplies and services 2,013,795 2,619,324
Sales of small instruments and supplies 1,021,162 1,103,294
Royalty revenue 21,835 88,127
----------- -----------
Net revenues 3,925,931 6,290,035
----------- -----------
Cost of goods - IVD imaging systems 481,940 1,228,110
Cost of goods - IVD imaging supplies and services 1,030,901 1,459,414
Cost of goods - sales of small instruments and supplies 528,408 573,474
----------- -----------
Cost of goods sold 2,041,249 3,260,998
----------- -----------
Gross margin 1,884,682 3,029,037
Marketing and selling 790,057 1,166,841
General and administrative 390,902 998,076
Research and development 270,103 455,965
Intangibles amortization 69,054 311,868
Unusual charges 199,365 95,129
----------- -----------
Total operating expenses 1,719,481 3,027,879
Operating income 165,201 1,158
Other income (expense):
Interest income 59,799 19,682
Interest expense (5,366) (310,744)
Other income 5,980 --
----------- -----------
Income (loss) before provision (benefit) for income taxes 225,614 (289,904)
Provision (benefit) for income taxes 18,702 (87,829)
----------- -----------
Net income (loss) 206,912 (202,075)
Less imputed preferred stock dividend -- (450,000)
----------- -----------
Net income (loss) available to common shareholders $ 206,912 $ (652,075)
=========== ===========
Net income (loss) per common share, after deduction
of imputed dividend on preferred stock $ .03 $ (.11)
=========== ===========
Weighted average number of common shares and common
share equivalents outstanding for the period 6,513,281 5,932,176
=========== ===========
</TABLE>
- --------------
The accompanying notes are an integral part of these consolidated financial
statements.
3
<PAGE> 5
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
<TABLE>
<CAPTION>
For the three months ended March 31,
1996 1997
----------- -----------
<S> <C> <C>
Cash flows from operating activities:
Net income (loss) $ 206,912 $ (202,075)
Adjustments to reconcile net income (loss) to cash provided by
operations:
Deferred tax benefit -- (121,000)
Depreciation and amortization 106,329 657,459
Common stock and stock option compensation 29,036 48,109
Changes in assets and liabilities:
Accounts receivable - trade and other (1,540,159) 519,150
Service contracts, net (81,190) 143,027
Inventories (435,311) 401,235
Prepaid expenses and other current assets (22,165) 16,713
Other assets -- 5,559
Accounts payable 311,365 (1,211,091)
Accrued expenses (14,128) (41,038)
Deferred income - other 940,475 (52,495)
----------- -----------
Net cash provided (used) by operating activities (498,836) 163,553
----------- -----------
Cash flows from investing activities:
Acquisition of property and equipment (446,900) (37,228)
Acquisition of product line (213,700) --
Software development costs (146,876) (124,701)
Acquisition of other assets (162,999) (30,000)
Decrease in short term investments 119,869 267,589
----------- -----------
Net cash (used) provided by investing activities (850,606) 75,660
----------- -----------
Cash flow from financing activities:
Repayment of notes payable (310,633) (1,300,000)
Repurchase of common stock -- (545,057)
Issuance of common stock for cash 29,893 22,009
Issuance of common stock for cash under Employee Stock
Purchase Plan 61,445 102,163
Cash overdraft 57,342 --
Deferred offering costs -- (93,244)
----------- -----------
Net cash used by financing activities (161,953) (1,814,129)
----------- -----------
Effect of foreign currency fluctuation on cash and cash equivalents -- (9,591)
----------- -----------
Net decrease in cash and cash equivalents (1,511,395) (1,584,507)
Cash and cash equivalents at beginning of period 1,511,395 3,602,535
----------- -----------
Cash and cash equivalents at end of period $ -- $ 2,018,028
=========== ===========
Supplemental schedule of non cash activities:
Issuance of common stock in exchange for services $ -- $ 102,163
Issuance of common stock in satisfaction of accounts payable -- 80,000
Issuance of warrants to purchase common stock -- 64,500
Deferred offering costs not paid -- 186,496
Supplemental disclosure of cash flow information
Cash paid for interest 5,366 289,233
Cash paid for income taxes -- --
</TABLE>
- ----------------------
The accompanying notes are an integral part of these consolidated financial
statements.
4
<PAGE> 6
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. FORMATION AND BUSINESS OF THE COMPANY.
International Remote Imaging Systems, Inc. was incorporated in California
in 1979 and reincorporated during 1987 in Delaware. International Remote Imaging
Systems, Inc. and its subsidiaries (collectively "IRIS" or the "Company")
operate primarily in one segment. The Company designs, develops, manufactures
and markets in vitro diagnostic ("IVD") imaging equipment, including IVD imaging
systems based on patented and proprietary automated intelligent microscopy
("AIM") technology, and special purpose centrifuges and other small instruments
for automating microscopic procedures performed in clinical laboratories. AIM
combines the Company's capabilities in automated specimen presentation,
including its patented slideless microscope, and proprietary high-speed digital
processing hardware and software to classify and visually present images of
microscopic particles in easy-to-use displays. The Company's IVD imaging systems
are designed to provide customers with better and more rapid results and labor
cost-savings over manual methods of performing microscopy. The Company also
provides on-going service and supplies to support equipment sold. The Company's
products are sold directly and through distributors primarily to clinical,
hospital, veterinary, physicians offices and research laboratories in North
America.
On July 31, 1996, the Company, through a wholly owned subsidiary, PSI
Acquisition Corp., acquired the IVD imaging business of Perceptive Scientific
Instruments, Inc. for $9.5 million in cash (including $400,000 in acquisition
costs), issuance of a $7.0 million 8.25% subordinated note ("Subordinated Note")
and a five year warrant to purchase 875,000 shares of the Company's common stock
at $8.00 per share (valued for accounting purposes at $927,000,) ("the PSI
Acquisition"). The cash portion of the purchase price was paid primarily with
funds obtained from a bank under a $7.8 million term loan ("Term Loan") and a
new $1.5 million revolving line of credit ("Credit Facility"). The Company
subsequently changed the name of PSI Acquisition Corp. to Perceptive Scientific
Instruments, Inc. ("PSI").
PSI designs, develops, manufactures and markets IVD imaging systems for
biological, clinical and research applications. PSI's primary business is
providing cytogenetic analysis instrumentation and related services through
worldwide sales of its proprietary PowerGene product line. The PowerGene product
line is used in various procedures for chromosome analysis, including
karyotyping and DNA probe and comparative genomic hybridization analysis via
fluorescent in-situ hybridization methods. The PowerGene system is marketed in
North America from PSI's Houston headquarters and internationally through its
U.K. subsidiary.
The PSI Acquisition has been accounted for using the purchase method of
accounting, and accordingly, the purchase price has been allocated to the assets
purchased and the liabilities assumed based upon their estimated fair value at
the date of acquisition. The operating results of the acquired business of PSI
are included in the consolidated statement of operations from the date of
acquisition, August 1, 1996. Accordingly, PSI financial results are included in
the consolidated statement of operations for the quarter ended March 31, 1997
and are not included in the consolidated statement of operations for the
comparable period in the prior year.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES.
Basis of Presentation of Unaudited Interim Financial Statements:
In the opinion of the Company, the accompanying unaudited consolidated
financial statements contain all normal recurring adjustments necessary to
present fairly the financial position of the Company and subsidiaries as of
March 31, 1997 and the results of their operations and cash flows for the three
months ended March 31, 1997 and 1996. It is suggested that these financial
statements be read in conjunction with the financial statements and notes
included in the latest Company's annual report on Form 10-K. Interim results are
not necessarily indicative of results for a full year.
5
<PAGE> 7
Use of Estimates:
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amount of revenues and expenses during the reporting
periods. Actual results could differ from those estimates.
Principles of Consolidation:
The consolidated financial statements include the accounts of International
Remote Imaging Systems, Inc. and its wholly-owned subsidiaries. All significant
intercompany accounts and transactions have been eliminated in the consolidated
financial statements.
Reclassifications:
Certain reclassifications have been made to the 1996 financial statements to
conform with the 1997 presentation.
3. INVENTORIES.
Inventories are carried at the lower of cost or market, on a first-in,
first-out basis and are composed of the following:
<TABLE>
<CAPTION>
At December 31, 1996 At March 31, 1997
-------------------- --------------------
<S> <C> <C>
Finished goods $ 631,116 $ 591,869
Work-in-process 646,031 724,280
Raw materials, parts and
sub-assemblies 3,561,059 3,114,204
---------- ----------
$4,838,206 $4,430,353
========== ==========
</TABLE>
4. PURCHASED INTANGIBLES.
Purchased intangibles, at cost, consist of the following:
<TABLE>
<CAPTION>
At December 31, 1996 At March 31, 1997
-------------------- --------------------
<S> <C> <C>
Goodwill $ 1,377,973 $ 1,377,973
International distribution
channel 5,571,728 5,571,728
Acquired technology
and know-how 3,960,904 3,960,904
------------ ------------
10,910,605 10,910,605
Less accumulated
amortization (585,845) (840,988)
------------ ------------
Total $ 10,324,760 $ 10,069,617
============ ============
</TABLE>
5. SHORT TERM BORROWINGS AND NOTES PAYABLE.
The Company financed the purchase price for the PSI Acquisition with the
Subordinated Note ($7.0 million), the Term Loan ($7.8 million) and the Credit
Facility ($1.3 million). The Term Loan and Credit Facility impose certain
operating and financial convenants on the Company. Due to an inability to comply
with these financial covenants, the Company was in default on both loans at
September 30 and December 31, 1996. In April of 1997, the bank waived the
default, amended the financial covenants and extended the maturity of both
loans. In exchange, the Company agreed to increase the interest rates on both
loans and to issue the bank a three year warrant to purchase 50,000 shares of
Common Stock at $3.875 per share. The Company also agreed to issue additional
warrants to purchase 25,000 shares of Common Stock at prevailing market prices
on each of June 1 and July 1, 1997 if the Term Loan is still outstanding on
those dates.
6
<PAGE> 8
On March 31, 1997 the outstanding principal balance of the Term Loan was
$4.7 million. The Term Loan is collateralized by a first priority lien on all
the assets of the Company and bears interest monthly at the bank's prime rate
(8.50% on March 31, 1997) plus 1.5%. The interest rate increases an additional
0.25 percentage points on each of June 1 and July 1, 1997. The Company is
required to pay $100,000 of principal each month, and the balance is due April
15, 1998. The Company may prepay the Term Loan at any time without premium or
penalty. The Company has further reduced the outstanding principal balance of
the Term Loan to $4.1 million as of May 11, 1997.
The outstanding principal balance on the Credit Facility was $1.3 million on
March 31, 1997. Under the terms of the Credit Facility, the Company can borrow
and reborrow up to a maximum principal amount of $1.5 million at a variable
interest rate equal to the bank's prime rate plus 1.5%. The interest rate
increases an additional 0.25 percentage points on each of June 1 and July 1,
1997 if the Term Loan is still outstanding on those dates. The Credit Facility
matures April 15, 1998 and is collateralized by a first priority lien on all of
the assets of the Company.
The outstanding principal balance on the Subordinated Note was $7.0 million
on March 31, 1997. The Subordinated Note bears interest at a fixed rate of 8.5%
per annum, payable in quarterly installments. The entire principal is due on or
before July 31, 2001.
The Company is presently pursuing additional financing to repay principal on
its outstanding indebtedness and to fund its long-term business strategy. The
Company may not be able to secure adequate additional financing on favorable
terms, if at all.
6. CAPITAL STOCK.
Stock Issuances:
During the quarter ended March 31, 1997, the Company issued 48,287 shares
of common stock in exchange for $204,326, in cash and services under the
Employee Stock Purchase Plan. Also, for the quarter ended March 31, 1997,
options to purchase 62,700 shares of common stock were granted under the 1997
Stock Option Plan. Options for 9,934 shares of common stock were exercised and
options for 13,800 shares of common stock were canceled. At March 31, 1997,
options to purchase 1,063,000 shares of common stock were issued and outstanding
under the Company's stock options plans. The outstanding options expire by the
end of 2007. The exercise price for these options ranges from $2.59 to $3.72 per
share, or an aggregate of $3.3 million. At March 31, 1997, there were 347,667
shares of common stock available for the granting of future options.
For the quarter ended March 31, 1997, 21,277 shares of common stock were
issued in satisfaction of accounts payable totaling $80,000.
Warrants:
At March 31, 1997, there were warrants outstanding and exercisable to
purchase 75,000 shares at $8.125 per share until March 30, 1998, 512,000 shares
at $6.50 per share until September 29, 1998, 150,000 shares at $7.80 per share
until September 28, 2000, 875,000 shares at $8.00 per share until July 31, 2001,
84,270 shares at $3.56 per share until December 31, 2001 and 50,000 shares at
$3.875 per share until January 15, 2000.
As part of the purchase price for the PSI Acquisition, the Company issued
the seller a five-year warrant to purchase 875,000 shares of common stock at
$8.00 per share. Following the Company's restatement in the third quarter of
1996 of financial results for certain prior periods, the Company received a
request from the seller for a reduction in the exercise price of the warrant. In
its request, the seller asserts that it had relied on the prior financial
information and suffered material damage as a result. The Company has declined
to consider the seller's request until the Company has evaluated its claims
against the seller.
7. RESEARCH AND DEVELOPMENT GRANTS AND CONTRACTS.
Reimbursements and direct costs connected with research and development
grants and agreements were as follows:
7
<PAGE> 9
<TABLE>
<CAPTION>
For the Three Months Ended March 31,
------------------------------------
1996 1997
-------- --------
<S> <C> <C>
Reimbursements $812,687 $312,538
Costs 822,318 339,205
-------- --------
Net costs $ 9,631 $ 26,667
======== ========
</TABLE>
Net costs incurred under research and development grants and contracts have
been included in research and development expense in the statements of
operations.
8. UNUSUAL CHARGES.
The results of operations for the three month period ended March 31, 1997
include unusual charges totaling $95,129 and are primarily legal expenses
relating to the recently completed litigation and arbitration matters. The
unusual charges in the comparable period in the prior year totalled $199,365 and
primarily related to StatSpin merger expenses.
9. INCOME TAXES
The income tax benefit for the quarter ended March 31, 1997 was
approximately $88,000 as compared to an income tax provision of approximately
$19,000 for 1996. The income tax benefit for the quarter ended March 31, 1997
differs from the federal statutory rate due to state, local and foreign income
taxes incurred on taxable income at a subsidiary level which is not offset by
losses at the corporate level.
10. EARNINGS PER SHARE.
The computations of share amounts for the three month periods ended March
31, 1997 are based on the weighted average number of shares outstanding for the
period. Common shares equivalents were not included in the computation as their
inclusion would be antidilutive.
The staff of the Securities and Exchange Commission recently announced a new
position on accounting for convertible preferred stock which is potentially
convertible at a discount to the market price of the common stock, even if the
potential for a discount is only a possibility. The staff has taken the position
that solely for purposes of calculating earnings per share the potential
discount is an imputed dividend to the preferred stockholders which reduces the
amount of earnings available to common stockholders. Accordingly, the issuance
of the Series A Preferred Stock resulted in a one-time reduction in earnings
available to common shareholders of $450,000 or $0.08 per share in the quarter
ended March 31, 1997. The staff's position is limited to calculations of
earnings per common share and will not have any effect on the Company's net
income and cash flow.
The computation of share amounts for the three months ended March 31, 1996
is based on the weighted average number of shares and common share equivalents
outstanding for the period.
11. RECENTLY-ISSUED ACCOUNTING STANDARD
In February, 1997, the Financial Accounting Standards Board issued
Statement of Financial Accounting Standards No. 128 "Earnings per Share" ("SFAS
No. 128"). SFAS No. 128 requires dual presentation of newly defined basic and
diluted earnings per share on the face of the income statement for all entities
with complex capital structures. This method is considered more compatible with
International Accounting Standards. SFAS No. 128 is effective for all fiscal
years ending after December 15, 1997. Due to the net loss incurred, the adoption
of SFAS No. 128 for the quarter ended March 31, 1997 would not have had an
impact on net loss per share. The Company has not yet determined the impact of
SFAS No. 128 for the quarter ended March 31, 1997.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
OVERVIEW
The Company generates revenues from sales of in vitro diagnostic ("IVD")
imaging systems based on its patented and proprietary AIM technology. Following
the initial sale, these systems become part of the "installed base" and generate
follow-on sales of supplies and service necessary for their operation. The
Company also generates revenues from sales of ancillary lines of small
laboratory instruments and supplies.
Until recently, the Company generated most of its revenues from sales of two
models of The Yellow IRIS urinalysis workstation and related supplies and
services. These two models differ mainly by their speed and price. In 1996, the
Company introduced a third model of The Yellow IRIS. The Model 900UDx urine
pathology system, the latest in The Yellow IRIS family, is a higher capacity
automated urinalysis workstation designed especially for the high-volume testing
requirements of large hospitals and reference laboratories. The Company received
FDA clearance to market the Model 900UDx in March 1996 and began sales in May of
that year. The Company also received FDA clearance to market The White IRIS
leukocyte differential analyzer in May 1996 and expects to start sales of this
system in 1997. Finally, the Company began selling the PowerGene family of
genetic analyzers in August 1996 after completing the acquisition, ("the PSI
Acquisition") of the digital imaging business of Perceptive Scientific
Instruments, Inc.
8
<PAGE> 10
The Company invests in research and development for new products and
enhancements to existing products. The following table summarizes total product
technology expenditures for the periods indicated:
<TABLE>
<CAPTION>
For the Three Months Ended March 31,
1996 1997
---------- ----------
<S> <C> <C>
Research and development expense, net ............. $ 270,103 $ 455,965
Capitalized software development costs ............ 146,876 124,701
Reimbursed costs for research and
development grants and contracts .................. 812,687 312,538
---------- ----------
Total product technology expenditures ...... $1,229,666 $ 893,204
========== ==========
</TABLE>
The Company partially funds its research and development programs through
(i) grants from NASA and NIH, (ii) joint development programs with strategic
partners and (iii) Company-sponsored research and development entities.
RESULTS OF OPERATIONS
The consolidated financial statements also reflect the consummation of the
PSI Acquisition on July 31, 1996 which was accounted for using the purchase
method of accounting. Accordingly, PSI financial results are included in the
consolidated statement of operations for the quarter ended March 31, 1997 but
are not included in the consolidated statement of operations for the comparable
period in the prior year.
Comparison of Quarter Ended March 31, 1997 to Quarter Ended March 31, 1996
Net sales for the first quarter ended March 31, 1997 increased to $6.3
million from $3.9 million, an increase of $2.4 million or 60% over the
comparable period in the prior year. Sales of IVD imaging systems increased to
$2.5 million from $869,000, an increase of $1.6 million or 185% over the
comparable period in the prior year. The increase was due primarily to the
addition of the PowerGene family of genetic analyzers to the Company's product
line in August 1996 as a result of the PSI Acquisition as well as
increases in sales of The Yellow IRIS. However, the Company believes that the
ongoing consolidation in the healthcare industry may adversely affect sales
of The Yellow IRIS as some hospitals and reference laboratories appear to be
postponing large capital investment decisions due to the resulting
uncertainty. The Company also believes that there is a growing trend among
potential customers for The Yellow IRIS toward leasing these systems on a
cost-per-test basis rather than purchasing them. This trend is expected to
spread the revenue from system placements over several years.
Sales of IVD imaging system supplies and services increased to $2.6 million
from $2.0 million, an increase of $600,000 or 30% over the comparable period in
the prior year, due to the larger installed base of IVD imaging systems and the
conversion of The Yellow IRIS installed base to the new CHEMSTRIP/IRIStrip urine
test strips marketed exclusively by the Company. As of March 31, 1997, the
Company had converted more than 90% of this installed base from test strips
marketed by various distributors to the new strips. Sales of small instruments
and supplies increased to $1.1 million from $1.0 million, an increase of
$100,000 or 8%, over the comparable period in the prior year. The increase
reflects generally higher sales levels of the StatSpin products, as well as the
addition of the CenSlide product line in March 1996.
Royalty revenues for the first quarter ended March 31, 1997 increased to
$88,000 from $22,000, an increase of $66,000 over the comparable period in the
prior year. The increase is primarily the result of increased revenues subject
to royalties and payment of royalties relating to the fourth quarter of 1996
which were previously in dispute.
Cost of goods for IVD imaging systems decreased as a percentage of sales of
IVD imaging systems to 50% for the quarter ended March 31, 1997 from 55% for the
comparable period in the prior year due primarily to the addition to the
Company's product line of the higher-margin PowerGene family of genetic
analyzers following the PSI Acquisition and an increase in the average selling
price of the Model 900UDX following the conclusion of its introductory sales
program.
9
<PAGE> 11
These factors were partially offset by the addition of the Model 900UDx to the
product line and amortization of increased fixed costs for IVD imaging systems.
Although the Model 900UDx currently has a lower gross margin than other models
of The Yellow IRIS due to an OEM component on which the Company recognizes
minimal gross margin, the Company expects the Model 900UDx to generate higher
sales of CHEMSTRIP/IRIStrips and other supplies. Cost of goods for IVD imaging
system supplies and services increased as a percentage of sales of such products
to 56% for the quarter ended March 31, 1997 from 51% for the comparable period
in the prior year primarily due to relatively lower gross margins on sales of
CHEMSTRIP/IRIStrip urine test strips which accounted for a greater proportion of
sales of system supplies and lower gross margins realized on the sales of
PowerGene service and supplies. Cost of goods for small instruments and supplies
as a percentage of sales of small instruments and supplies totaled 52% for the
quarter ended March 31, 1997 and is comparable to the quarter ended March 31,
1996. The net result of these changes resulted in an aggregate gross margin of
48% for the quarter ended March 31, 1997, which is comparable to the gross
margin realized in the quarter ended March 31, 1996.
Marketing and selling expenses consist primarily of salaries, commissions
and related travel expenses of the Company's direct sales force, as well as
salaries for the marketing and distributor relations departments. Marketing and
selling expenses increased to $1.2 million for the quarter ended March 31, 1997
from $790,000, an increase of $372,000 or 47% over the comparable period in the
prior year, due to the addition of the sales force from the PSI Acquisition.
Marketing and selling expenses as a percentage of net revenues decreased from
20% in the prior period to 18% in the current period.
General and administrative expenses consist primarily of payroll costs
associated with the Company's management and support personnel, facilities
related costs and legal and accounting fees. General and administrative expenses
increased to $998,000 for the quarter ended March 31, 1997 from $391,000, an
increase of $607,000 or 155% over the comparable period in the prior year, and
increased as a percentage of net revenues from 10% to 16%. This increase is the
result of the addition of the administrative functions following the PSI
Acquisition, increased administrative staffing and increased legal and
accounting expenses.
Net research and development expenses consist of costs incurred for the
development of new products and improvements to existing products less
third-party reimbursements under joint development programs, grants and research
and development contracts. Net research and development expenses increased to
$456,000 for the quarter ended March 31, 1997 from $270,000, an increase of
$186,000 or 69% over the comparable period in the prior year, and remained
constant as a percentage of net revenues at 7%. Reimbursements under joint
development programs decreased to $313,000 from $813,000. Total product
technology expenditures decreased to $893,000 from $1.2 million, a decrease of
$336,000 or 27% over the comparable period in the prior year, due primarily to
completion of sponsored work on the Model 900UDx. The decreases were partially
offset by increases in expenditures relating to the addition of the research and
development staff following the PSI Acquisition.
Amortization of intangible assets reflects the amortization of deferred
expenses for warrants issued in connection with joint development projects and
intangible assets arising from acquisitions and patents. Amortization of
intangible assets for the quarter ended March 31, 1997 increased to $312,000
from $69,000, an increase of $243,000 or 352% over the comparable period in the
prior year, primarily as a result of the acquisition of intangible assets in the
PSI Acquisition.
The results of operations for the quarter ended March 31, 1997 include
certain unusual charges to earnings of $95,000, primarily legal expenses
relating to recently completed litigation and arbitration matters. The unusual
charges in the comparable period in the prior year totaled $199,000, related
primarily to StatSpin merger expenses.
Interest income consists of income from investments and decreased to $20,000
for the quarter ended March 31, 1997 from $60,000 for the comparable period in
the prior year, primarily as the result of decreased amounts of invested cash in
1997.
Interest expense increased to $311,000 for the quarter ended March 31, 1997
from $5,000 for the comparable period in the prior year due to the indebtedness
incurred to finance the PSI Acquisition.
The income tax benefit for the quarter ended March 31, 1997 was $88,000, as
compared to an income tax provision of $19,000 for 1996. The income tax benefit
for the quarter ended March 31, 1997 differs from
10
<PAGE> 12
the federal statutory rate due to state, local and foreign income taxes incurred
on taxable income at a subsidiary level which is not offset by losses at the
corporate level.
The staff of the Securities and Exchange Commission recently announced a new
position on accounting for convertible preferred stock which is potentially
convertible at a discount to the market price of the common stock, even if the
potential for a discount is only a possibility. The staff has taken the position
that, solely for purposes of calculating earnings per share, the potential
discount is an imputed dividend to the preferred stockholders which reduces the
amount of income available to common stockholders. As a result of the staff's
new accounting position, the issuance of the Series A Preferred Stock resulted
in a one-time reduction in earnings available to common shareholders of $450,000
or $0.08 per share in the first quarter of 1997. The staff's position is limited
to the calculation of earnings per share and did not have any effect on the
Company's net income or cash flow.
The above factors contributed to a net loss of $202,000 or $0.11 per share
for the quarter ended March 31, 1997 as compared to net income of $207,000 or
$0.03 per share for the quarter ended March 31, 1996.
LIQUIDITY AND CAPITAL RESOURCES
Cash, cash equivalents and short-term investments decreased to $2.4 million
at March 31, 1997 from $4.3 million at December 31, 1996. The decrease is
primarily attributable to repayment of notes payable and payments for purchase
of common stock. Inventory levels during the first quarter of 1997 decreased to
$4.4 million from $4.8 million at December 31, 1996. This decrease is primarily
due to the implementation of an inventory reduction program. Total accounts
receivable decreased to $4.6 million at March 31, 1997 from $5.2 million at
December 31, 1996. This decrease was primarily the result of improved collection
efforts.
Accounts payable decreased to $3.5 million at March 31, 1997 from $4.6
million at December 31, 1996 primarily due to the application of the net
proceeds from the sale of the Series A Preferred Stock in late December 1996.
Cash provided by operations totaled $164,000 for the quarter ended March 31,
1997, as compared to cash used in operations totaling $499,000 in the quarter
ended March 31, 1996.
In the first quarter of 1997, the Company expended $37,000 for capital
equipment and $125,000 in capitalized software development. The Company expended
$447,000 for capital equipment and $147,000 in capitalized software development
in the comparable quarter of the prior year. The Company does not presently have
any material commitments for capital expenditures.
During the first quarter of 1997, the Company generated cash of $124,000
from stock sales to employees under the Company's stock option and purchase
plans.
On March 31, 1997, the outstanding principal balance of the Term Loan was
$4.7 million. The Term Loan is collateralized by a first priority lien on all
the assets of the Company and bears interest monthly at the bank's prime rate
(8.50% on April 1, 1997) plus 1.5%. The interest rate increases an additional
0.25 percentage points on each of June 1 and July 1, 1997. The Company is
required to pay $100,000 of principal each month, and the balance is due April
15, 1998. The Company may prepay the Term Loan at any time without premium or
penalty. The Company has further reduced the outstanding principal balance of
the Term Loan to $4.1 million as of May 11, 1997.
The outstanding principal balance on the Credit Facility was $1.3 million on
March 31, 1997. Under the terms of the Credit Facility, the Company can borrow
and reborrow up to a maximum principal amount of $1.5 million at a variable
interest rate equal to the bank's prime rate plus 1.5%. The interest rate
increases an additional 0.25 percentage points on each of June 1 and July 1,
1997 if the Term Loan is still outstanding on those dates. The Credit Facility,
collateralized by a first priority lien on all assets, matures April 15, 1998.
On March 31, 1997, the Company owed approximately $1.0 million for the
repurchase of common stock and warrants to purchase common stock from an
affiliate of Boehringer Mannheim Corporation. This balance is due in two
installments in the second half of 1997. The Company has the right, if
necessary, to extend the due dates of the remaining installments by one year
each, but must pay 8% interest during the extension periods.
11
<PAGE> 13
The Company believes that its current cash on hand plus short-term
investments, together with cash generated by operations, will be sufficient to
fund normal operations and pay interest on outstanding debt obligations for at
least the next year.
The Company is presently pursuing additional financing to repay outstanding
principal on its long-term indebtedness and to fund its long-term business
strategy. The Company may not be able to secure adequate additional financing on
favorable terms, if at all. Additional outside financing (or a restructuring of
existing indebtedness) could result in dilution to holders of Common Stock and
significant financial and operational restrictions on the Company.
In September 1995, the Company and Poly UA Systems Inc. ("Poly"), entered
into a research and development agreement to develop the Poly products using the
Company's technology. The Company is funding the first $15,000 per month (up to
a maximum of $500,000) of the cost of the project, and Poly is reimbursing the
Company for the excess. The Company has an option to acquire all of the common
stock of Poly for an aggregate price increasing on August 1, 1997 from $4.4
million to $5.1 million, payable in cash or shares of Common Stock of the
Company. If the Company elects to exercise its option, the portion of the net
cost of the acquisition allocated to completed products would be capitalized and
its subsequent amortization may impact future earnings to extend profits from
products acquired do not cover these costs. For the portion of the net cost of
the acquisition allocated to in-process research and development, the Company
would record a nonrecurring, noncash (if purchased with Common Stock) charge
against then current earnings.
INFLATION
The Company does not foresee any material impact on its operations from
inflation.
HEALTHCARE REFORM POLICIES
In recent years, an increasing number of legislative proposals have been
introduced or proposed in Congress and in some state legislatures that would
effect major changes in the healthcare system, nationally, at the state level or
both. Future legislation, regulation or payment policies of Medicare, Medicaid,
private health insurance plans, health maintenance organizations and other
third-party payors could adversely affect the demand for the Company's current
or future products and its ability to sell its products on a profitable basis.
Moreover, healthcare legislation is an area of extensive and dynamic change, and
the Company cannot predict future legislative changes in the healthcare field or
their impact on its business.
RECENTLY-ISSUED ACCOUNTING STANDARD
In February, 1997, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards No. 128 "Earnings per Share" ("SFAS No. 128").
SFAS No. 128 requires dual presentation of newly defined basic and diluted
earnings per share on the face of the income statement for all entities with
complex capital structures. This method is considered more compatible with
International Accounting Standards. SFAS No. 128 is effective for all fiscal
years ending after December 15, 1997. Due to the net loss incurred, the
adoption of SFAS No. 128 for the quarter ended March 31, 1997 would not have
had an impact on net loss per share. The Company has not yet determined the
impact of SFAS No. 128 for the quarter ended March 31, 1997.
FORWARD-LOOKING STATEMENTS
The foregoing discussion, as well as the other sections of this Annual
Report on Form 10-Q, contain various forward-looking statements which reflect
the Company's current views with respect to future events and financial results.
Forward-looking statements usually include the verbs "anticipates," "believes,"
"estimates," "expects," "intends," "plans," "projects," "understands" and other
verbs suggesting uncertainty. The Company reminds stockholders that
forward-looking statements are merely predictions and therefore inherently
subject to uncertainties and other factors which could cause the actual results
to differ materially from the forward-looking statement. The Company has
attempted to identify these uncertainties and other factors in its 1996 Annual
Report on Form 10-K.
12
<PAGE> 14
PART 2 OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
The Company is involved in routine litigation arising in the ordinary course
of its business, and, while the results of the proceedings cannot be predicted
with certainty, the Company believes that the final outcome of such matters will
not have a material adverse effect on the Company.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
(a) Exhibits
No. Description
3.1(a) -- Certificate of Incorporation, as amended (1)
3.1(b) -- Certificate of Designations of Series A Convertible Preferred
Stock (2)
3.2 -- Restated Bylaws (3)
4.1 -- Specimen of Common Stock Certificate (4)
4.2 -- Certificate of Designations of Series A Convertible Preferred
Stock (2)
11 -- Statement re: Computation of Per Share Earnings
27 -- Financial Data Schedule
- -------------------
The following items are incorporated by reference to the cited Company
documents.
(1) Current Report on Form 8-K dated August 13, 1987 and its Quarterly
Report on Form 10-Q for the quarter ended September 30, 1993.
(2) Current Report on Form 8-K dated January 15, 1997.
(3) Quarterly Report on Form 10-Q for the quarter ended September 30, 1994.
(4) Registration Statement on Form S-3, as filed with the Securities and
Exchange Commission on March 27, 1996 (File No. 333-002001).
(b) Reports on Form 8-K
During the quarter ended March 31, 1997, the Company filed a report on Form
8-K on January 15, 1997 to report the sale of 3,000 shares of Series A
Convertible Preferred Stock and Warrants to the Thermo Amex Convertible Growth
Fund I, L.P.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized, in Chatsworth, California, on May 14,
1997.
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
By: /s/ Martin S. McDermut
Martin S. McDermut, Vice President, Finance
& Administration and Chief Financial Officer
13
<PAGE> 1
EXHIBIT 11
STATEMENT OF COMPUTATION OF PER SHARE EARNINGS
<TABLE>
<CAPTION>
Three months ended March 31,
1996 1997
--------- ---------
<S> <C> <C>
Actual Weighted Average Shares Outstanding for the Period
Dilutive Effects of Stock Options and Warrants Using Average 6,244,673 5,932,176
Market Price 268,608 Antidilutive
----------- ------------
Total Shares Based on Shares Outstanding and the
Assumption that All Share Equivalents Are Exercised at
Average Stock Market Price 6,513,281 5,932,176
Additional Dilutive Effect of Stock Options and Warrants Being
Exercised Using Ending Market Price -- --
----------- -----------
Total Shares Based on Shares Outstanding and the
Assumption That All Stock Options and Warrants are
Exercised at Ending Market Price 6,513,281 5,932,176
=========== ===========
Net Income (Loss) Applicable to Fully Diluted Earnings Per Share $ 206,912 $ (652,075)
=========== ===========
Fully Diluted Net Income (Loss) Per Share $ .03 $ (.11)
=========== ===========
</TABLE>
14
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AT MARCH 31, 1997 AND THE CONSOLIDATED STATEMENT OF
OPERATION FOR THE PERIOD ENDED MARCH 31, 1997 AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> MAR-31-1997
<CASH> 2,018,028
<SECURITIES> 400,000
<RECEIVABLES> 4,581,301
<ALLOWANCES> 285,819
<INVENTORY> 4,430,353
<CURRENT-ASSETS> 12,633,934
<PP&E> 5,357,201
<DEPRECIATION> 3,638,743
<TOTAL-ASSETS> 34,877,147
<CURRENT-LIABILITIES> 10,719,261
<BONDS> 0
0
30
<COMMON> 59,913
<OTHER-SE> 13,782,840
<TOTAL-LIABILITY-AND-EQUITY> 34,877,147
<SALES> 5,353,053
<TOTAL-REVENUES> 6,290,035
<CGS> 3,260,998
<TOTAL-COSTS> 3,022,879
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 310,744
<INCOME-PRETAX> (289,904)
<INCOME-TAX> (87,829)
<INCOME-CONTINUING> (202,075)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (202,075)
<EPS-PRIMARY> (.11)
<EPS-DILUTED> (.11)
</TABLE>
